Profitable Presbyopia
Presbyopia is no longer a condition we simply accommodate; it has become a platform for a longitudinal relationship that can span decades.
-
By
-
Lisa M. Nijm, MD, JD
-
January 1, 2026
-
Clinical Scorecard: Profitable Presbyopia
At a Glance
| Category | Detail |
|---|
| Condition | Presbyopia |
| Key Mechanisms | Pharmacologic correction, intraocular lens advancements, diagnostic improvements |
| Target Population | Patients experiencing presbyopia |
| Care Setting | Ophthalmology practices |
Key Highlights
- Approval of pilocarpine 1.25% ophthalmic solution for pharmacologic presbyopia correction
- Introduction of combination pharmacologic therapy with carbachol and brimonidine
- Refinement of extended-depth-of-focus lenses and enhanced monofocals
- Importance of ocular surface optimization before any presbyopia intervention
- Advancements in diagnostic precision with anterior segment imaging and AI assistance
Guideline-Based Recommendations
Diagnosis
- Utilize advanced diagnostics such as wavefront analysis and pupillometry
Management
- Consider pharmacologic options for situational near-vision support
- Evaluate corneal refractive approaches for patients not ready for lens-based surgery
Monitoring & Follow-up
- Follow up with patients using topical presbyopia agents to engage in further treatment discussions
Risks
- Ensure identification and treatment of ocular surface issues to prevent dissatisfaction with interventions
Patient & Prescribing Data
Patients with presbyopia seeking vision correction
Pharmacologic agents provide flexibility and can serve as a bridge to surgical options
Clinical Best Practices
- Optimize ocular surface health before initiating presbyopia treatment
- Individualize treatment selection based on patient lifestyle and visual goals
- Engage patients in ongoing discussions about their vision and treatment options
Related Resources & Content
